OBJECTIVE: To determine the efficacy and safety of Actitropil (fonturacetam) in asthenia. MATERIAL AND METHODS: This meta-analysis includes the studies results on fonturacetam efficacy in asthenia. After checking for the risk of bias and the risk of systematic errors, the meta-analysis included 11 articles. The efficacy and safety of fonturacetam at a daily dose of 200 mg was assessed, since patients received this dose in all included studies. RESULTS: The meta-analysis included 549 patients (mean age 45.9 years, 95% CI: 38.1-53.7). In all studies, the level of asthenia according to the MFI-20 scale was significantly reduced after a course of fonturacetam (one month course, assessment on the thirtieth day from the beginning of treatment), by an average of 16.3 points (95% CI: 8.85-23.85 points) ( CONCLUSION: Fonturacetam effectively reduces the level of asthenic syndrome after a month of therapy.